Kate has over 15 years of experience as a life science consulting leader. She has leveraged her background in health policy, biostatistics and epidemiology to help pharmaceutical and biotech organizations optimize their development and commercial strategies.
Over the course of her career, Kate has led engagements spanning numerous diagnostic and therapeutic areas, with a focus on inflammation and immunology, neurology, and rare diseases across the U.S., the European Union and emerging markets. Her experience in epidemiology, qualitative research and data analytics has been instrumental in providing biotech and pharmaceutical clients with insights across the value chain, from initial trial planning to post-launch commercialization.
Prior to joining Huron, Kate was principal at The Frankel Group in New York City. Kate holds a bachelor’s degree in public policy from The University of Chicago and a master’s degree in public health, with a focus on epidemiology, from Yale University.